Thus, there seems to be an interesting crosstalk of EGFR-TGF-β and PD-1 which could be further explored in head and neck cancers and other cancer types treated with anti-EGFR or pembrolizumab alone [123]. Here, TGFB1 is linked to head and neck cancer.